Clinical Trial Update: Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating autologous T cells engineered to target mesothelin in malignant pleural mesothelioma. The study is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Autologous mesothelin-targeted CAR-T cells

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Malignant Pleural Disease, Mesothelioma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING